• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酵母聚糖激活血清与肝素在诱导多形核白细胞聚集方面的协同作用。

Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation.

作者信息

Berliner S, Fishelson Z, Wasserman L, Pinkhas J, Aronson M

机构信息

Department of Internal Medicine D, Beilinson Medical Center, Rehovot, Israel.

出版信息

Biomed Pharmacother. 1988;42(1):69-72.

PMID:3408808
Abstract

During the course of extracorporeal circulation, leukocyte aggregation is known to occur in some patients. This is attributed to complement activation and release of the chemotactic factor C5a. We investigated the effect of heparin on in vitro complement induced aggregation of polymorphonuclear leukocytes (PMNAGG), since most patients undergo heparinization during the extracorporeal circulation. Our results indicate that sub-aggregating concentrations of zymosan-activated serum (ZAS) enhance heparin-induced PMNAGG and that sub-aggregating amounts of heparin increase the aggregation induced by ZAS. Heat inactivation of the serum prior to zymosan activation abrogated the aggregating activity of the ZAS. Furthermore, the combined ZAS and heparin-induced PMNAGG was partially inhibited by specific antibodies to C5a but not to C3a. Therefore, we suggest that heparin and C5a may have a synergistic effect on the aggregation of polymorphonuclear leukocytes. These data might be relevant to situations in which patients are subjected to extracorporeal circulation.

摘要

在体外循环过程中,已知一些患者会发生白细胞聚集。这归因于补体激活和趋化因子C5a的释放。由于大多数患者在体外循环期间接受肝素化,我们研究了肝素对体外补体诱导的多形核白细胞聚集(PMNAGG)的影响。我们的结果表明,酵母聚糖激活血清(ZAS)的亚聚集浓度会增强肝素诱导的PMNAGG,而亚聚集量的肝素会增加ZAS诱导的聚集。酵母聚糖激活前血清的热灭活消除了ZAS的聚集活性。此外,ZAS和肝素联合诱导的PMNAGG被抗C5a特异性抗体部分抑制,但抗C3a抗体则无此作用。因此,我们认为肝素和C5a可能对多形核白细胞的聚集具有协同作用。这些数据可能与患者接受体外循环的情况相关。

相似文献

1
Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation.酵母聚糖激活血清与肝素在诱导多形核白细胞聚集方面的协同作用。
Biomed Pharmacother. 1988;42(1):69-72.
2
Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: chemotaxis, chemiluminescence, and lysosomal enzyme release.抗C5a抗体对人多形核白细胞功能的影响:趋化作用、化学发光及溶酶体酶释放
J Biol Response Mod. 1989 Dec;8(6):614-24.
3
Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.补体(C5-a)诱导的体外粒细胞聚集。补体介导的白细胞停滞和白细胞减少的一种可能机制。
J Clin Invest. 1977 Jul;60(1):260-4. doi: 10.1172/JCI108763.
4
Role of granulocytes and C5a in myocardial response to zymosan-activated serum.粒细胞和C5a在心肌对酵母聚糖激活血清反应中的作用。
Am J Physiol. 1991 Jul;261(1 Pt 2):H29-37. doi: 10.1152/ajpheart.1991.261.1.H29.
5
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.系统性红斑狼疮患者血清中补体(C5)衍生趋化活性的特异性抑制剂。
J Clin Invest. 1978 Jul;62(1):29-38. doi: 10.1172/JCI109110.
6
Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.牛血浆、血清和乳中C5a/C5a(去精氨酸)的定量分析。
Vet Res. 1998 Jan-Feb;29(1):73-88.
7
The release of C5a in complement-activated serum does not require C6.补体激活血清中C5a的释放不需要C6。
J Immunol. 1989 Aug 15;143(4):1228-32.
8
The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis.肝素及相关糖胺聚糖对中性粒细胞趋化性的抑制作用。
Thromb Haemost. 1984 Oct 31;52(2):134-7.
9
Cellular reactivity of polymorphonuclear leukocytes in psoriasis and atopic dermatitis--measurement of lucigenin-dependent chemiluminescence.银屑病和特应性皮炎中多形核白细胞的细胞反应性——光泽精依赖性化学发光的测定
Acta Derm Venereol. 1986;66(4):285-9.
10
Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.趋化肽可调节人类多形核白细胞对培养的内皮细胞单层的黏附。
J Immunol. 1986 May 1;136(9):3412-9.